| Annual Financials | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 2,159 | 3,223 | 4,336 | 5,530 | 5,694 |
| Expenses | 2,329 | 3,179 | 4,225 | 5,292 | 5,553 |
| EBITDA | -170 | 45 | 111 | 238 | 141 |
| Operating Profit % | -10 % | -1 % | -1 % | 1 % | -10 % |
| Depreciation | 27 | 32 | 29 | 25 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -197 | 13 | 82 | 214 | 141 |
| Tax | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -197 | 13 | 82 | 214 | 141 |
| EPS in ₹ | -1.42 | 0.09 | 0.51 | 1.22 | 0.80 |
Niva Bupa Health Insurance Company
Niva Bupa Health Insurance Company
84.13
+2.87
(3.53%)
Market Cap
15,522.45 Cr
EPS
1.22
PE Ratio
106.99
Dividend Yield
0.00 %
Industry
Insurance52 Week High
109.34
52 Week Low
68.54
PB Ratio
4.88
Debt to Equity
0.42
Sector
General Insurance
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from5 analysts
Company News
View All News
Niva Bupa Health Insurance announced it will not immediately increase premiums following the GST Council's decision to exempt individual life and health insurance from tax effective September 22. The GST exemption provides customers an 18% benefit, representing about one-fifth of previously paid premiums. Executive Director Ankur Kharbanda stated the company wants to assess the impact before making any premium changes, particularly regarding unclear input tax credit provisions for insurers. The exemption removes GST from various insurance policies that previously carried rates ranging from 1.8% to 18%. Niva Bupa's market capitalization stands at ₹15,474 crore, with shares trading at ₹88.79 and gaining 19% over the past year.
Niva Bupa Health Insurance responded to a viral LinkedIn post claiming the company denied a ₹61 lakh cashless claim for bone marrow cancer treatment. The insurer stated it approved ₹25 lakh pre-authorization plus ₹77,000 additional amount, with the original approval remaining valid. The patient Chandra Kumar Jain has been a policyholder since November 2021, and two earlier claims totaling ₹22.72 lakh were already paid in 2025. Niva Bupa raised queries when treatment costs escalated from ₹25 lakh to ₹61 lakh and then nearly ₹80 lakh by September 1. The company asked the hospital not to demand additional payments until cost escalation is clarified. Separately, Niva Bupa suspended cashless treatment at Max Hospitals from August 16, 2025 after their contract expired in May due to pricing disagreements. Max Healthcare said it continues providing cashless treatment despite the expired contract but noted that Niva Bupa requested further tariff reductions beyond 2022 levels, which Max considers unviable.
Niva Bupa has suspended cashless treatment facilities at all Max Hospitals across India, effective August 16, 2025. The suspension follows the expiration of their agreement in May 2025, with ongoing discussions on tariff revisions failing to reach mutual agreement. Customers will now need to pay medical bills upfront and seek reimbursement instead of direct cashless settlement. The insurer maintains cashless services at over 10,400 other network hospitals and has introduced priority reimbursement processing for Max Hospital treatments. Star Health and Care Health customers also reportedly face similar cashless unavailability at Max Hospitals. Niva Bupa is actively working with Max Hospitals to resolve the issue.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,838.20 | #1 91,264.52 | 34.80 | 24,000.80 | 16.45 | 2,508 | 28.72 | 45.11 | |
365.15 | 64,061.92 | #1 7.52 | #1 49,924.60 | -2.50 | #1 6,974 | #1 80.67 | 38.33 | |
352.65 | 32,554.44 | 71.24 | 9,695.50 | 12.54 | 425 | 36.53 | 47.33 | |
195.23 | 32,173.90 | 27.54 | 43,634.00 | 0.32 | 972 | 65.38 | 59.24 | |
445.00 | 26,157.39 | 44.28 | 16,113.00 | 15.90 | 646 | -17.69 | 52.27 | |
84.13 | #6 15,522.45 | #6 106.99 | #6 5,529.70 | #1 27.52 | #6 214 | #6 -386.17 | 43.55 |
Forecast
Actual
Growth Rate
Revenue Growth
27.52 %
Net Income Growth
161.00 %
Cash Flow Change
103.55 %
ROE
106.20 %
ROCE
31.84 %
EBITDA Margin (Avg.)
67.70 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,782 | 1,078 | 2,301 | 3,308 |
| Fixed Assets | 49 | 52 | 58 | 66 |
| Current Assets | 287 | 455 | 675 | 1,510 |
| Capital Work in Progress | 1 | 4 | 1 | 9 |
| Investments | 2,401 | 3,366 | 5,458 | 8,175 |
| Other Assets | -669 | -2,344 | -3,216 | -4,943 |
| Total Liabilities | 1,782 | 1,078 | 2,301 | 3,308 |
| Current Liabilities | 1,983 | 2,799 | 3,891 | 6,452 |
| Non Current Liabilities | 250 | 250 | -682 | -469 |
| Total Equity | 1,532 | 828 | 2,983 | 3,776 |
| Reserve & Surplus | 125 | -680 | 1,282 | 1,950 |
| Share Capital | 1,409 | 1,511 | 1,700 | 1,827 |
Cash Flow
| Cash Flow | 2017 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 4 | 164 | -12 | 43 | 41 | 78 |
| Investing Activities | -32 | -374 | -723 | -829 | -1,882 | -2,348 |
| Operating Activities | 8 | 257 | 338 | 593 | 813 | 1,654 |
| Financing Activities | 28 | 281 | 374 | 280 | 1,110 | 771 |
Share Holding
| % Holding | Jun 2024 | Nov 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 62.94 % | 55.98 % | 55.98 % | 55.98 % | 55.43 % |
| FIIs | 0.00 % | 8.63 % | 8.85 % | 8.90 % | 10.76 % |
| DIIs | 0.00 % | 9.57 % | 9.83 % | 9.70 % | 15.06 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.71 % | 4.43 % | 4.23 % | 5.44 % |
| Others | 37.06 % | 21.12 % | 20.92 % | 21.19 % | 13.30 % |
| No of Share Holders | 86 | 1,60,440 | 1,46,255 | 1,36,017 | 1,54,883 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 31 Mar 2022 |  Change Of Name | NA | 31 Mar 2022 | 0.00 | 0.00 |
| 25 Nov 2024 |  Quarterly Result Announcement | NA | 25 Nov 2024 | 73.95 | 73.72 |
| 04 Feb 2025 | Quarterly Result Announcement | NA | 04 Feb 2025 | 76.34 | 81.17 |
| 07 May 2025 | Quarterly Result Announcement | NA | 07 May 2025 | 82.33 | 80.85 |
| 31 Jul 2025 | Quarterly Result Announcement | NA | 31 Jul 2025 | 86.84 | 85.17 |
| 26 Aug 2025 |  Annual General Meeting | NA | 26 Aug 2025 | 85.17 | 83.96 |
Announcements
Announcement under Regulation 30 (LODR)-Cessation
8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
8 days agoShareholder Meeting / Postal Ballot-Scrutinizers Report8 days ago
8 days agoShareholder Meeting / Postal Ballot-Outcome of AGM9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call TranscriptAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 02, 2025
Aug 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Aug 01, 2025Grant Of Stock OptionsAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 31, 2025
Jul 31, 2025Letter To Shareholders Regarding Notice Of The 17Th Annual General MeetingJul 31, 2025
Jul 31, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 31, 2025
Jul 31, 2025Reg. 34 (1) Annual Report.Jul 31, 2025
Jul 31, 2025Notice Of 17Th AGM Scheduled To Be Held On Tuesday August 26 2025 At 02:30 P.M.(IST) Through VC/OAVMJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJul 31, 2025
Jul 31, 2025Statement Of Deviation/Variation- Quarter Ended June 30 2025Jul 31, 2025
Jul 31, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On July 31 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 24, 2025
Jul 24, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results For The Quarter Ended June 30 2025.Jul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorJul 21, 2025
Jul 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 14, 2025
Jul 14, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jul 03, 2025
Jul 03, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 30, 2025
Jun 30, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Credit RatingJun 27, 2025
Jun 27, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJun 14, 2025
Jun 14, 2025Announcement under Regulation 30 (LODR)-Resignation of DirectorJun 09, 2025
Jun 09, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 04, 2025
Jun 04, 2025Reporting Of Sale Of SharesJun 03, 2025
Jun 03, 2025Grant Of Employee Stock OptionsMay 29, 2025
May 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
May 28, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 13, 2025
May 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 08, 2025
May 08, 2025Amendment To The Code Of Practices And Procedures For Fair Disclosure Of UPSIMay 07, 2025
May 07, 2025Appointment Of Secretarial AuditorsMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 07, 2025
May 07, 2025Grant Of Employee Stock Options To Eligible EmployeesMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 07, 2025
May 07, 2025Board Meeting Outcome for Outcome Of Board Meeting- Audited Standalone Financial Results For Quarter And Year Ended March 31 2025May 07, 2025
May 07, 2025Technical Indicators
RSI(14)
Neutral 43.55
ATR(14)
Volatile 2.98
STOCH(9,6)
Oversold 19.23
STOCH RSI(14)
Neutral 32.30
MACD(12,26)
Bearish -0.05
ADX(14)
Weak Trend 23.54
UO(9)
Bearish 30.86
ROC(12)
Downtrend And Accelerating -5.83
WillR(14)
Oversold -87.96
Mutual Fund Holdings
Bajaj Finserv Small Cap Fund Direct-Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
DSP Dynamic Asset Allocation Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
SBI Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth 
Kotak Nifty Smallcap 250 Index Fund Direct-Growth 
Groww Nifty Smallcap 250 Index Fund Direct - Growth 
Axis Nifty 500 Index Fund Direct-Growth 
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
Helios Mid Cap Fund Direct-Growth 
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
